Cytokinetics (CYTK) Misses Q1 EPS by 2c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $85.46 +3.98%
Revenue Growth %: -75.4%
Financial Fact:
Net loss: 31.89M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Revenue Growth %: -75.4%
Financial Fact:
Net loss: 31.89M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q1 EPS of ($1.67), $0.02 worse than the analyst estimate of ($1.65). Revenue for the quarter came in at $19.35 million versus the consensus estimate of $8.59 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Upgrades Cytokinetics (CYTK) to Buy
- Gilat Satellite Networks (GILT) call put ratio 5.5 calls to 1 put as share price up 5.4%
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
